Oct 2026· JCO Oncology Practice· Vol 22, pp. 117-117· 0 citations
TL;DR
Barriers to EPCT participation among a group of minoritized trial participants and caregivers were driven by a combination of limited awareness, language barriers, logistical intensity, fear of uncertainty, and historical distrust.
Abstract
117
Background:
Early phase clinical trials (EPCTs) are critical for oncology innovation and access to novel therapies, yet members of minoritized communities remain underrepresented as a result of complex psychosocial, structural, and systemic barriers. Understanding the varying perspectives of patients, caregivers, and clinicians is essential to improving equitable access.
Methods:
As part of a qualitative study regarding community navigators for minoritized potential EPCT participants, focus groups were conducted in English and Spanish with EPCT participants (n=5) who self-identified as Hispanic or Black and caregivers of such patients (n=4). Semi-structured interviews were also conducted with clinicians (n=5) in the Mount Sinai Early Phase Trials Unit. Transcripts were coded in ATLAS.ti, employing thematic analysis to identify core drivers of trial participation and refusal.
Results:
Analysis revealed four primary thematic domains: communications gap, systemic and language barriers, altruism vs. fear of the unknown, and trust between clinicians and patients. Communications gap: Patients and caregivers reported profound initial lack of familiarity with EPCTs and clinical trials in general. Clinicians highlighted common fundamental misunderstanding of Phase I goals which they perceived as exacerbated by low health literacy and socioeconomic status. Systemic and Language Barriers: Language discordance emerged as a critical barrier; clinicians admitted to offering trials less frequently to non-English speakers due to time constraints and "cold" interpreter interactions. Clinicians noted that logistical burdens, specifically frequent visits, transportation, and associated costs disproportionately affected lower-income families, while patients and caregivers described few practical burdens. Altruism vs Fear of the Unknown: Patients and caregivers characterized decision-making as a tension between fear (of being a "guinea pig" or experiencing unknown toxicity) and hope. Participants frequently cited altruism and the perception of having "nothing to lose" or being in a state of desperation as primary motivators. Trust as a Mediator: The clinician-patient relationship was the strongest facilitator of enrollment. Patients relied heavily on the recommendation of their primary oncologist, while clinicians used transparency to build trust with minoritized groups.
Conclusions:
Barriers to EPCT participation among a group of minoritized trial participants and caregivers were driven by a combination of limited awareness, language barriers, logistical intensity, fear of uncertainty, and historical distrust. To foster equitable access, clinical teams must move beyond "equal offering" toward equitable support using education, language concordant materials and personnel, and trust-building with patients and families.
118
Background:
Black and Hispanic patients remain underrepresented in early-phase cancer clinical trials (EPCTs), limiting equitable access to novel therapies. Building on a pilot study of a community navigator (CN)-led intervention that was feasible, acceptable, and had positive stakeholder feedback, we condu...
Marina Serrano Fernandez, I. Yao, Taira Anderson et al.· JCO Oncology Practice· 0 citations
Multiple myeloma (MM) is a complex, costly hematologic cancer with well-documented health disparities in patient outcomes. We conducted a qualitative study to capture stakeholders’ perspectives on care barriers and potential solutions to inform interventions that improve accessibility and affordability, particula...
Meera Muthukrishnan, Shelbie Fishman, R. Vij et al.· Cancer Epidemiology, Biomark...· 0 citations
Background Interest in using patients’ own mobile devices for electronic patient-reported outcome (ePRO) collection in multi-site oncology clinical trials is growing. Clinical Research Professionals (CRPs) play a key role in supporting patients’ use of ePRO systems, yet their perspectives remain underexplored. Objectiv...
Youmin Cho, Yun Jiang, D. Arnault et al.· Therapeutic Innovation and...· 0 citations
As part of a multi-phase behavioral interventional study aimed at improving rates of clinical trial (CT) participation amongst patients (pts) from historically underrepresented groups (HUGS), hematology/oncology attending providers at our institution were offered participation in a 1:1 randomized study evaluating...
S. Nakhoda, M. Albert, Nicole Harrington et al.· Cancer Epidemiology, Biomark...· 0 citations
This is one of the first studies to explore user design and AAC considerations in patients with TRA and highlights the importance of minimizing cognitive burden, supporting care-partner involvement, and designing adaptive AAC tools for the progressive nature of aphasia in neuro-oncology.
John Y. Rhee, Amy J. Maguire, Paul J. Miller et al.· JCO Oncology Practice· 0 citations
Prostate cancer is a leading cause of cancer-related morbidity and mortality globally, with disproportionately poor outcomes in low- and middle-income countries due to late presentation, limited awareness, and barriers to treatment. In Botswana, there is limited evidence on patient experiences and culturally approp...
Lebogang Laletsang-Mokokwe, Y. Martei, T. Ralefala et al.· JCO Global Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.